Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-12-24, Stock:PFE, The news for the past five days is as follows:
2019-12-17: NEWS1: Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know.NEWS2: Colorado life science companies brought in more than $12 billion in 2019.NEWS3: S&P 500, Dow and Nasdaq score fresh records at close.NEWS4: Morphic Holding Tabbed as Likely to Develop Blockbuster Drug.NEWS5: Pfizer wins FDA approval for 'first and only' oral treatment for prostate cancer drug.NEWS6: Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts.NEWS7: Pfizer's Xtandi Gets FDA Nod for Expanded Patient Group.NEWS8: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO.NEWS9: Markets Extend Rally, Led by Tech Sector.
2019-12-18: NEWS1: 3 Top Dogs of the Dow Stocks to Own Heading Into 2020.NEWS2: U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy.NEWS3: Pfizer and Mylan Announce Two Future Viatris Board Members.NEWS4: Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020.
2019-12-19: NEWS1: Pfizer's Braftovi sNDA Accepted by FDA for Priority Review.
2019-12-20: NEWS1: 10 2019 Losers That Will Be 2020 Winners.NEWS2: Caterpillar, Merck share gains contribute to Dow's nearly 100-point jump.NEWS3: Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs.NEWS4: Troubled Traders.
2019-12-23: NEWS1: Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know.NEWS2: GlaxoSmithKline's Long-Acting HIV Regimen Gets CRL From FDA.NEWS3: Bristol-Myers' Revlimid Combo Gets EU Nod for New Indication.NEWS4: Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program.

Answer: Decrease